Intelligent Investor

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

Current share price for NEU : $18.920 0.75 (3.81%)

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
$2,416 Application for quotation of securities - NEU 8 Apr 2024 4:26PM $20.800 $18.920 $20.760 fallen by 9.04%
$2,416 Application for quotation of securities - NEU 12 Mar 2024 2:24PM $20.740 $18.920 $20.760 fallen by 8.78%
$2,416 2023 Results webinar 29 Feb 2024 4:17PM $19.360 $18.920 $20.760 fallen by 2.27%
$2,416 Neuren reports profit of $157 million for 2023 29 Feb 2024 3:40PM $19.360 $18.920 $20.760 fallen by 2.27%
$2,416 Appendix 4E and 2023 full year accounts 29 Feb 2024 3:36PM $19.360 $18.920 $20.760 fallen by 2.27%
$2,416 Neuren 2023 results investor webinar on 29 February 2024 29 Feb 2024 9:27AM $19.150 $18.920 $20.760 fallen by 1.20%
$2,416 DAYBUE net sales US$87.1 million in Q4 2023 28 Feb 2024 9:54AM $21.480 $18.920 $20.760 fallen by 11.92%
$2,416 Comment on research report 16 Feb 2024 1:02PM $20.040 $18.920 $20.760 fallen by 5.59%
$2,416 Pause in Trading 16 Feb 2024 10:57AM $20.290 $18.920 $20.760 fallen by 6.75%
$2,416 Notification regarding unquoted securities - NEU 8 Feb 2024 4:37PM $22.420 $18.920 $20.760 fallen by 15.61%
$2,416 Application for quotation of securities - NEU 1 Feb 2024 4:31PM $23.040 $18.920 $20.760 fallen by 17.88%
$2,416 Q4 2023 Appendix 4C Cash Flow Report 31 Jan 2024 1:26PM $23.565 $18.920 $20.760 fallen by 19.71%
$2,416 Q4 2023 quarterly activity report 31 Jan 2024 1:09PM $23.500 $18.920 $20.760 fallen by 19.49%
$2,416 Completion of enrolment in Neuren's Angelman P2 trial 20 Dec 2023 9:12AM $23.960 $18.920 $20.760 fallen by 21.04%
$2,416 Application for quotation of securities - NEU 19 Dec 2023 4:17PM $23.960 $18.920 $20.760 fallen by 21.04%
$2,416 Investor presentation, 18 December 2023 18 Dec 2023 9:11AM $17.140 $18.920 $20.760 risen by 10.39%
$2,416 P2 trial shows significant improvements in Phelan-McDermid 18 Dec 2023 9:02AM $17.140 $18.920 $20.760 risen by 10.39%
$2,416 Trading Halt 14 Dec 2023 9:24AM $17.140 $18.920 $20.760 risen by 10.39%
$2,416 Neuren completes enrolment in Pitt Hopkins Phase 2 trial 5 Dec 2023 8:55AM $16.110 $18.920 $20.760 risen by 17.44%
$2,416 Comment on media speculation 20 Nov 2023 10:14AM $14.890 $18.920 $20.760 risen by 27.07%
$2,416 Neuren completes Phelan-McDermid syndrome Phase 2 trial 13 Nov 2023 9:45AM $14.460 $18.920 $20.760 risen by 30.84%
$2,416 Investor presentation, 8 November 2023 8 Nov 2023 9:20AM $12.750 $18.920 $20.760 risen by 48.39%
$2,416 DAYBUE net sales US$66.9 million in Q3 2023 3 Nov 2023 9:59AM $11.290 $18.920 $20.760 risen by 67.58%
$2,416 Q3 2023 quarterly activity and cash flow report 20 Oct 2023 9:30AM $11.490 $18.920 $20.760 risen by 64.66%
$2,416 Change of Director's Interest Notice - J Basile 14 Sep 2023 9:19AM $11.470 $18.920 $20.760 risen by 64.95%

1 - 25 of 586 results

Page 1 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.